MDM2 and CDK4 amplification is a potential therapeutic target in these tumours with ongoing Phase I and II trials of CDK4 and/or MDM2 inhibitors, but there are no established treatment options developed yet based on these genetic alterations [9]. This evidence concerns the gene MDM2 and neoplasm.